Navigation Links
CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
Date:11/3/2008

- Data presented at the 2008 iSBTc Annual Meeting -

- Conference call to be hosted today at 11:00 a.m. ET to discuss results -

BRANFORD, Conn., Nov. 3 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today preliminary data from an ongoing Phase II trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, for the treatment of patients with unresectable Stage III or Stage IV melanoma. Dr. Patrick Hwu, Co-Principal Investigator, and Professor and Chairman of the Department of Melanoma Medical Oncology, at The University of Texas M. D. Anderson Cancer Center, presented the data during an oral session at the 2008 International Society for Biologic Therapy of Cancer (iSBTc) Annual Meeting.

Thirty-six patients were enrolled into this Phase II open-label, multi-center trial that is evaluating the efficacy and safety of CR011-vcMMAE 1.88 mg/kg administered intravenously once every three weeks. Eligible patients had progressive disease at trial entry and may have received one prior cytotoxic regimen and any number of prior immunotherapies. Of the patients enrolled, 94% had Stage IV disease of which two-thirds were classified as M1c, the poorest risk group.

At the time of the data cutoff for this analysis (19 Sept 2008), 31 patients had at least one efficacy assessment available, and 18 patients were continuing to receive ongoing treatment in the study. The median overall progression-free survival (PFS) to date was approximately 4.5 months. RECIST-defined partial responses were reported in 3 patients, 2 ongoing, and an unconfirmed partial response in 1 patient. Nineteen patients had stable disease, 14 ongoing, with tumor shrinkage observed in 12 of these patients.

"PFS is a cli
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
(Date:5/23/2013)... -- Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: HADSY), a ... intellectual property developed and owned by Hadassah University ... research center, today announced that its portfolio company, ... the Israeli Ministry of Industry and Commerce, Office ... development and advance clinical trials. Cell Cure,s development ...
(Date:5/23/2013)... , May 23, 2013  Texas, premier physician ... deliver doctors the survival tools they need to provide ... in today,s health care marketplace. "I am ... save local practices," said Stephen L. Brotherton ... (TMA). " Texas doctors are determined ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2TMA Launches Physician Services Organization for Patient Care 2TMA Launches Physician Services Organization for Patient Care 3TMA Launches Physician Services Organization for Patient Care 4
... WASHINGTON, Oct. 16 The Post and Courier ... bus tour visited the Piggly Wiggly at 445 Meeting Street ... about programs that provide free or nearly free prescription medications. ... Partnership for Prescription Assistance , a nationwide effort sponsored ...
... Medco Health Solutions, Inc (NYSE: MHS ) today ... non-profit organization to support activities aimed at educating and ... safety issues; providing low income, disadvantaged and other distressed ... about medicine; and fostering and promoting opportunities for volunteerism ...
Cached Medicine Technology:The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 2The Medco Foundation Joins With the Entertainment Industry Foundation to 'Give Health a Hand' to Communities in Need 3
(Date:5/25/2013)... According to an article in the June 2013 issue ... million Americans tan indoors each year and an unknown number ... health risks. New research suggests that UV rays may ... brains of some tanners (Go to goo.gl/hdwnz). , “There ... say that I fully support this contention from a scientific ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today ... lift skin on the neck, on the brow and under ... Aesthetics. , Ultherapy is a non-surgical procedure for the face ... to lift the skin over time. The use of FDA-cleared ... and then treat the deepest support layers of the skin ...
(Date:5/25/2013)... A disorder of the nerves, Diabetic neuropathy ... to neuropathy expert doctor Helen C Lin, on Medscape ... disorder affects almost 50% of all Diabetic patients, making ... high blood sugar levels in the body are the ... usually tend to have abnormally high blood sugar levels. ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market ... Ingredients, Shell Materials, Packaging, & Geography: Trends & ... market with analysis and forecasting of the global ... driving and restraining factors for the global food ... challenges. The market is segmented and revenue are ...
(Date:5/25/2013)... May 25, 2013 Absolute Surgical Specialists, serving ... of the NALA’s businesses throughout the country participating in Shop ... participate in the nationwide event as he understands what military ... in the Army. He said, “I wanted to give something ... serve, but I live here too.” , Shop Local for ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... cause damage to the brain of youngsters, says a ... misuse can do to them. // ,Thomas Heffernan, ... students for the research presented at the British Psychological ... of Daily Mail. ,Half the students ...
... research team from the New York University College of Dentistry ... oral decay evolved along with its human hosts. ... common ancestor who lived in Africa between 100,000 and 200,000 ... by Page Caufield, a professor of cariology and comprehensive care ...
... in EMBO says that the parasite that is responsible ... new pathway. Sleeping sickness is caused by Trypanosoma brucei ... ,Shulamit Michaeli and colleagues describe a pathway in T. ... this pathway shuts down the synthesis of a crucial ...
... the healthcare sector with a super-specialty hospital in Gurgaon,// on ... of Rs.2.1 billion ($45 million). ,Christened Artemis Health ... will open next month. "In the second phase, another 240 ... of AHS. ,"This is the first of similar ...
... governments to join the anti-tuberculosis global plan, which would ... disease has become extremely drug-resistant. ,Ban's message ... on Saturday. The World Health Organization (WHO) recently reported ... of tuberculosis, XDR-TB, which threatens to derail efforts to ...
... be hampered if they indulge in excessive drinking.// This ... a psychologist from Northumbria University. ,Alcohol and ... young age which could extend into adulthood. According to ... a very crucial stage. ,Dr. Thomas Heffernan ...
Cached Medicine News:Health News:Tooth Decay Bacteria Evolved Along With Man 2
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... The VITROS ECi brings true automation ... immunodiagnostic testing. Highly sensitive assays for ... and bone metabolism testing are currently ... development. The VITROS ECi can simultaneously ...
IRMA kit for detection of the cardiac marker Myoglobin...
... is intended for the quantitative determination of ... useful in the diagnosis and treatment of ... The BioCheck Prolactin Quantitative Test is based ... enzyme-linked immunosorbent assay. The assay system utilized ...
Medicine Products: